Carcinoma, Hepatocellular ; physiopathology ; Humans ; Liver ; physiopathology ; Liver Function Tests ; methods ; Liver Neoplasms ; physiopathology ; Preoperative Care

Surgical resection is the best treatment for hepatocarcinoma. With the rapid development and cooperation of multi-disciplines, the liver surgery gradually towards a precise stage, and accurate evaluation of regional liver function preoperatively is demand for the development of precise liver surgery. Methods to assess function of liver at present include serological liver function and biochemical examination, clinical liver function scoring system, quantitative liver function test and imaging examination. Nuclide imaging technology and liver specificity enhanced MRI contrast agent are expected to achieve to evaluate regional liver function.
Carcinoma, Hepatocellular ; physiopathology ; Contrast Media ; Liver Function Tests ; Liver Neoplasms ; physiopathology ; Magnetic Resonance Imaging ; Sensitivity and Specificity

OBJECTIVE: To identify the differentially expressed genes (DEGs) in peripheral blood mononuclear cells (PBMC) of patients with hepatocellular carcinoma (HCC) and to analyze their regulatory network. METHODS: The DEGs in PBMCs of HCC patients were screened based on GEO database. The functional enrichment analysis and interaction analysis were carried out for DEGs. MCODE algorithm was used to screen core genes of DEGs, and the mirDIP and starBase online tools were used to predict upstream miRNAs and lncRNAs of the core genes. RESULTS: A total of 265 DEGs with a high credibility were identified, which were mainly enriched in the biological activity, such as regulation of cell proliferation, metabolic regulation, cell communication and signaling, and inflammatory diseases according to Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, and the two analyses were correlated. Four diagnostic candidate genes were identified, including FUS RNA binding protein, C-X-C motif chemokine ligand 8, cullin 1 and RNA polymerase Ⅱ subunit H. Subsequently, 10 miRNAs, 1 lncRNAs and 38 circRNAs were predicted, and finally a lncRNA/circRNA-miRNA-mRNA-pathway regulatory networks was constructed. CONCLUSIONS The diagnostic candidate genes and its regulatory network in HCC PBMC have been identified based on data mining, which could provide potential tumor biomarkers for early diagnosis and treatment of HCC.
Carcinoma, Hepatocellular ; physiopathology ; Gene Expression Regulation, Neoplastic ; Gene Regulatory Networks ; Humans ; Leukocytes, Mononuclear ; metabolism ; Liver Neoplasms ; physiopathology

Blood Vessels ; chemistry ; physiopathology ; Carcinoma, Hepatocellular ; metabolism ; physiopathology ; Elasticity ; Humans ; Liver Neoplasms ; metabolism ; physiopathology ; Rupture, Spontaneous ; metabolism ; physiopathology ; von Willebrand Factor ; metabolism

OBJECTIVETo improve the resectable rate of massive hepatic tumors and operative tolerance of hepatectomy in the treatment of advanced liver cancers.

METHODSSixteen cases of massive hepatic tumors were reviewed. The selective exclusion of hepatic outflow and inflow in hepatectomy was discussed.

RESULTSAll the patients had normal course after the operative procedure and no hepatic coma or other severe hepatic disturbances were observed.

CONCLUSIONWhile the selective exclusion of hepatic outflow and inflow were applied, the resectable rate of massive hepatic tumors and operative tolerance of hepatectomy were improved.

Adult ; Carcinoma, Hepatocellular ; physiopathology ; surgery ; Female ; Hemangioma, Cavernous ; physiopathology ; surgery ; Hepatectomy ; methods ; Hepatic Artery ; surgery ; Hepatic Veins ; surgery ; Humans ; Liver Circulation ; Liver Neoplasms ; physiopathology ; surgery ; Male ; Middle Aged

Combined hepatocellular-cholangiocarcinoma is a rare form of primary liver cancer showing features of both hepatocellular and biliary epithelial differentiation. We report here on a case with collision tumor, which apparently was the coincidental occurrence of both hepatocellular carcinoma and cholangiocarcinoma underlying schistosomiasis. A 39-year-old-Philippine female was transferred to our hospital for evaluation of a liver mass that was found on ultrasonography at a local hospital. HBsAg and Anti-HCV were negative and serum alpha-fetoprotein (AFP) level was normal. The tumor mass was histologically diagnosed as adenocarcinoma by sono-guided biopsy before the operation. Partial lobectomy was performed and we histologically identified the concurrent occurrence of hepatocellular carcinoma and cholangiocarcinoma, (a "collision type carcinoma").
Adenocarcinoma/diagnosis/pathology/surgery ; Adult ; Carcinoma, Hepatocellular/*diagnosis/pathology/surgery ; Cholangiocarcinoma/*diagnosis/pathology/surgery ; Female ; Humans ; Schistosomiasis/*physiopathology

Spontaneous regression of hepatocellular carcinoma is extremely rare, and the exact pathogenesis leading to this remarkable phenomenon remains unclear. We describe a case of spontaneous regression of an incidentally discovered hepatocellular carcinoma in a 63-year-old man with hepatitis C cirrhosis. The regression followed a series of events, in particular, an upper gastrointestinal haemorrhage. Ischaemic insult may be a major pathway leading to tumour regression. As limited data is available in the literature, knowledge and recognition of this rare event will have implications for patient management and may alter treatment. Further, data may be useful to assess if these patients have an altered prognosis with improved survival.
Carcinoma, Hepatocellular ; blood supply ; complications ; pathology ; physiopathology ; Gastrointestinal Hemorrhage ; etiology ; physiopathology ; Humans ; Incidental Findings ; Liver Cirrhosis ; complications ; pathology ; physiopathology ; Liver Neoplasms ; blood supply ; complications ; pathology ; physiopathology ; Male ; Middle Aged ; Neoplasm Regression, Spontaneous ; pathology ; physiopathology ; Tomography, X-Ray Computed

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is 3rd leading cause of cancer in Korea and the prognosis for HCC patients is poor. For assessing the present treatment outcome, this study analyzed the three-year survival rate (3-YSR) and the prognostic factors for patients with HCC in Korea. METHODS: Between November 2000 and December 2003, 905 patients with HCC who were diagnosed and treated at the National Cancer Center Korea were enrolled in this study. The clinical variables, tumor characteristics and survival periods were analyzed. RESULTS: The mean age of all patients was 56.2+/-10.3 years and 732 (80.9%) patients were male (M:F=4.2:1). 508 (56.1%) patients died and the median survival period was 15.3 months. The overall 3-YSR of the patients with modified UICC stage I, II, III, IVa and IVb were 67.4%, 65.2%, 30.7%, 9.0% and 5.0%, respectively. The modified UICC stage could not differentiate stage I from II, and stage IVa from IVb, on the 3-YSR. The 3-YSR of the Child-Pugh class A patients with modified UICC stage I or II was 85.4% by surgical resection and it was 69.6% by transcatheter chemoembolization (TACE), respectively (P= .461), and those values for patients with stage III were 49.2% and 36.8%, respectively (P=.081). As compared with systemic chemotherapy or conservative therapy, TACE increased the survival rate more for the Child-Pugh class A patients with stage IV. The independent prognostic factors were serum AFP, portal vein thrombosis, the Child-Pugh classification and the stage of HCC. CONCLUSIONS: This follow-up study will be helpful in assessing the results of treatments for HCC and it will provide data for the establishment of a more effective treatment strategy.
Survival Rate ; Survival Analysis ; Neoplasm Staging ; Middle Aged ; Male ; Liver Neoplasms/*mortality/pathology/physiopathology/therapy ; Humans ; Female ; Carcinoma, Hepatocellular/*mortality/pathology/physiopathology/therapy ; Aged

The intensive use of chemotherapeutic agents for the treatment of cancer has resulted in the cure or improved survival of many patients. But unfortunately, many cancers including human hepatocellular carcinoma (HCC) don't respond to chemotherapy. One of the major mechanisms for the drug resistance in the HCC is an elevated MDR1 RNA expression which makes cells become multidrug resistant. To overcome the multidrug resistance (MDR) phenotype, a high dose of verapamil is required both clinically and experimentally. Accordingly we have examined the MDR modulating effects with combinations of tamoxifen, cyclosporin A, and verapamil in vitro with the physiologically achievable concentrations of each agent, i.e., 2.0 microM/L for tamoxifen, 1.6 microM/L for cyclosporin A, and 2.5 microM/L for verapamil respectively in HCC lines. As expected, verapamil alone with the physiologically achievable concentration at which we tested didn't enhance the doxorubicin cytotoxicity in the HCC lines. Furthermore, any verapamil combination with cyclosporin A or tamoxifen was not effective in overcoming the doxorubicin resistance in the high MDR1 expressor (Hep-G2) line. However tamoxifen reduced the IC50 of doxorubicin by a factor of 1.9 in the low MDR1 expressor (SK-Hep1) and 1.1 in the high MDR1 expressor line (p< 10(-5) respectively). Of interest, combinations of tamoxifen and cyclosporin A showed a significant reduction in the IC50 of doxorubicin in both HCC lines. The IC50 of doxorubicin was reduced by a factor of 3.9 and 1.3, i.e., from 0.023943 micrograms/ml to 0.006157 micrograms/ml (p< 10(-5)) in the SK-Hep1 cell line, and 0.068819 micrograms/ml to 0.052442 micrograms/ml (p< 10(-5)) in Hep-G2 respectively when tamoxifen and cyclosporin A were administered together. Both the estrogen and progesterone receptors in the SK-Hep1 and Hep-G2 lines were less than 0.01 fmol/mg of cytosol protein, respectively. It is therefore suggested that the reversal of doxorubicin resistance is unrelated to their anti-estrogenic activity in the HCC lines. Three modulator combinations of tamoxifen, cyclosporin A, and verapamil were not more effective than the combination of tamoxifen and cyclosporin A on the sensitivity to doxorubicin. MDR modulators of tamoxifen, cyclosporin A, and verapamil didn't reduce the IC50 of cisplatin to the clinically achievable concentration range in HCC lines. In summary, the combination of tamoxifen and cyclosporin A at the concentrations normally seen after clinical administration of these modulators showed significant synergism on the sensitivity to doxorubicin in both low and high MDR1 expressor HCC lines. These data indicate the need for in vivo trials.
Antineoplastic Agents/*pharmacology ; Carcinoma, Hepatocellular/*physiopathology ; Cyclosporine/*pharmacology ; Drug Resistance ; Human ; Liver Neoplasms/*physiopathology ; Support, Non-U.S. Gov't ; Tamoxifen/*pharmacology ; Tumor Cells, Cultured/drug effects ; Verapamil/*pharmacology

Carcinoma, Hepatocellular ; blood supply ; diagnostic imaging ; Hepatic Artery ; physiopathology ; Humans ; Liver Neoplasms ; blood supply ; diagnostic imaging ; Portal Vein ; physiopathology ; Tomography, Spiral Computed ; methods